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Abstract
Background: Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor. Even
with vigorous surgery, radiation and chemotherapy treatment, survival rates of GBM are very poor and predictive
markers for prognosis are currently lacking.
Methods: We performed whole genome expression studies of 67 fresh frozen untreated GBM tumors and validated
results by 210 GBM samples’ expression data from The Cancer Genome Atlas.
Results and discussion: Here we show that in GBM patients, high metallothionein (MT) expression is associated with
poor survival whereas low MT levels correspond to good prognosis. Furthermore we show that in U87 GBM cell line, p53
is found to be in an inactive mutant-like conformation concurrently with more than 4 times higher MT3 expression level
than normal astrocytes and U251GBM cell line. We then show that U87- p53 inactivity can be rescued by zinc (Zn).
Conclusions: Taken together, these data suggest that MT expression may be a potential novel prognostic biomarker for
GBM, and that U87 cells may be a good model for patients with non active WT p53 resulting from high levels of MTs.
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Background
Glioblastoma multiforme (GBM) is the most common
and aggressive malignant brain tumor [1]. Survival rates
vary between studies (20.0 to 61.1 % at 1 year) and only
2 %–5 % of patients are expected to survive longer than
2 years [2]. Our understanding of these tumors has ex-
panded recently by efforts made by The Cancer Genome
Atlas (TCGA) and others [3]. These efforts have led to
the discovery of new molecular biomarkers for disease
prognosis including microRNAs dysregulation [4], methyl
guanine methyl transferase (MGMT) promoter methylation
[5] and mutations in isocitrate dehydrogenase 1 (IDH1),
EGFR, and p53 [6]. Nevertheless, the predictive ability of
outcome by imaging, clinical, and genomic biomarkers is
still only 69 % [7] and accordingly new biomarkers are
needed.
Metallothioneins (MTs) are intracellular heavy metal
binding proteins. Mammalian MTs fall into 4 subgroups:
MT1, MT2A, MT3, and MT4 [8]. MT1 encodes multiple
isoforms, MT1A, MT1B, MT1E, MT1F, MT1G, MT1H,
and MT1X [9]. MT1 and MT2 are expressed in nearly
all organs [9]. MT3 is preferentially expressed in the
brain, while MT4 expression appears to be limited to
squamous epithelial cells [10, 11]. MTs can bind 7 atoms
of zinc per molecule of protein [12] and affect the cellu-
lar zinc amount [13]. They also bind cytotoxic agents,
such as alkylating agents and confer resistance to these
anticancer drugs. MTs over expression has been linked
to chemo resistance in carcinoma cells, non-small cell
lung cancer cell lines, tongue squamous cell carcinoma
cell lines, gastric tumor cell lines, ovarian carcinoma cell
lines and osteosarcoma [14]. Elevated levels of MT1X,
MT1F, MT2A , MT1A, MT1E and MT3 were shown in
result of arsenic trioxide chemotherapy drug on U87
cells by Falnoga et al and postulated as potential mecha-
nisms for GBM resistance [15]. Furthermore, it has been
shown that the metal-free form of MT (apo-MT) may
also bind P53 and prevent its activity [16–18]. Elevated
levels of MT1E has also been shown to enhance the
migration and invasion of human glioma cells [19].
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MTs are negatively regulated by HIPK2 [13]. It was
previously reported that, in HIPK2 knockdown colon
cancer, breast cancer and ovarian cancer, p53 undergoes
misfolding which inhibits DNA binding and transcrip-
tional activities concurrently with increased chemoresis-
tance [20, 21]. In MCF7 breast cancer cells, HIPK2
knockdown is correlated with metallothionein 2A (MT2A)
up regulation. Inhibition of MT2A expression in these
cells by siRNA restores p53 transcription activity and
drug-induced apoptosis [13]. Since p53 activity is zinc
dependent, zinc deficiency may also halt p53 activity [20].
Absence of p53 activity, or expression of mutant p53
(mtp53) are common in human cancers and are associated
with increased cancer resistance to chemo- and radiother-
apy. Therefore, significant efforts towards pharmaceutical
reactivation of defective p53 pathways are underway
(reviewed in [22]). Zinc, for example, has been suggested
as it re-establishes chemo sensitivity in breast cancer
SKBR3 (expressing R175H mutation) and glioblastoma
U373MG (expressing R273H mutation) cell lines to adria-
mycin and cisplatin treatment, respectively [23].
The Cancer Genome Atlas (TCGA) study showed that
p53 and its pathway are altered in 78 % of GBMs [24].
p53 hotspot mutations include disruption of DNA inter-
action and DNA binding interface structure stabilization,
which can be restored to wild-type configuration by p53
reactivating treatments [25, 26]. For example, the R175H
mutant induces structural distortions in p53 protein that
prevent it from binding zinc [27]. It has been shown that
NSC319726 compound restores p53 (R175) mutant
structure to wild type conformation by its zinc ion
metallochaperone properties [28].
In this study we report that in GBM patients, high
metallothionein (MT) expression is associated with poor
survival whereas low MT levels correspond to good
prognosis. Furthermore we show that in U87 GBM cell
line may be a good model for patients with non active
WT p53 resulting from high levels of MTs.
Methods
Human subjects and cell lines: 67 fresh frozen untreated
GBM tumors and seven postmortem normal brain sam-
ples (subcortical white matter) from UCLA tumor bank
were used for the discovery set. Tissues were obtained at
the time of surgery in accordance with applicable human
ethics regulations approved by UCLA institutional review
board and after written informed consent were obtained.
Subjects were chosen to have similar condition and treat-
ment. Patients underwent maximal tumor resection,
received external beam regional radiation of 60 Gy within
3–6 weeks after resection, concurrent with temozolomide
(75 mg per square meter of body-surface area per day,
7 days per week from the first to the last day of radiother-
apy), followed by six cycles of adjuvant temozolomide
(150 to 200 mg per square meter for 5 days during each
28-day cycle). The median age at diagnosis was 53 years
and Karnofsky performance status (KPS) > 60. No patient
died from disease or other causes not related to their brain
tumor. The samples were snap frozen in liquid nitrogen.
In addition data from 210 TCGA GBM samples were
collected. The results shown here are based upon data
generated by the TCGA Research Network: http://cancer-
genome.nih.gov/. KPS was high in the TCGA data set with
a median value of 90. The median age at diagnosis for
TCGA samples was 57 years and there were 62 % males.
The human glioblastoma cell lines U87-MG (with wild
type p53) obtained from the American Type Culture
Collection (ATCC) and U251-MG (bearing mutant p53)
were developed in the laboratory of Dr. J. Ponten, Univer-
sity of Uppsala, Sweden. Normal astrocytes were a kind
gift of Dr. Chaya Brodie lab, Bar-Ilan Institute, Israel.
Microarray analysis: For the 67 discovery set, U95Av2
(Affymetrix, Santa Clara, CA) was used to interrogate
12,533 probe sets encoding 10,000 genes. Gene expres-
sion profiling studies of these samples were generated
according to standard Affymetrix protocols. DNA-Chip
Analyzer (dChip) (http://www.hsph.harvard.edu/cli/complab/
dchip/) program was used to obtain model based gene ex-
pression value (measures the fluorescence intensity of that
gene), then the class neighbors analysis standardizes the
expression values for each gene by linearly adjusting their
values across all samples to a mean of zero with a stand-
ard deviation of one. Individual genes are then clustered
using an algorithm in dChip program that determines the
correlation coefficients (r values) for the normalized
expression values (distances between genes are defined as
1 – r). Genes with the shortest distances between them are
grouped. The color scale for the resulting picture: the red
color represents expression level above mean expression of
a gene across all samples, the black color represents mean
expression and the green color represents expression lower
than the mean. Since the expression levels for each gene is
standardized to have mean 0 and standard deviation 1, the
standardized expression values fall within [-3, 3]. Thus in
the resulting picture, black represents 0, pure red repre-
sents 3 or higher and pure green represents -3 or lower
expression. After the discovery of genes that are predictive
of survival, their mean expression value were plotted and
compared between samples. In the clustering step the
comparison is between the patients according to the sur-
vival time. The value for normal sample expression is plot-
ted on the expression plot for base line orientation.
For the 210 TCGA GBM samples Affymetrix HT Human
Genome U133 expression data were loaded from TCGA
data portal (https://tcga-data.nci.nih.gov/tcga). Table 1 en-
lists Affymetrix probes used for MTs and HIPK2 analysis.
The TCGA Data Portal application, Data Browser, was used
to generate the Kaplan Meier curves.
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Quantitative real time PCR: qRT-PCR experiments of
human-derived GBM cell lines U251, U87 and normal
human astrocytes were performed. U251 and U87 Cell
lines were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) supplemented with 10 % fetal bovine
serum and 1 % penicillin/streptomycin. Normal human
astrocytes (NHA) served as controls and were cultured in
Astrocyte Basal Medium (ABM; Lonza) supplemented
with 0.1 % rhEGF, 0.25 % Insulin, 0.25 % Ascorbic Acid,
0.1 % GA-1000, 1 % L-Glutamine, 3 % FBS and 1 % peni-
cillin/streptomycin. All of the cell lines were cultured at
37 °C, in a 5 % CO2 atmosphere. Total RNA was extracted
from 5x105 cells using the RNeasy Mini Kit (Qiagen, USA)
following the manufacturer’s instructions. For quantization
and quality control we used the Agilent 2100 Bioanalyzer
(Agilent Thechnologies). A260/A280 Ratio of the RNA
was approximately 2 for all samples. 2 ng RNA was used
for reverse transcription by the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems - Life
Technologies USA). The resulting 2 ng cDNA was used
for the SYBR Green reagent-based RTPCR on Applied
Biosystems 7500 Real Time PCR System. The primers
that were used for MT3 RTPCR were: forward primer-
5’ACCTCCTGCAAGAAGAGCTG3’, reverse primer- 5’C
AGCTGCACTTCTCTGCTTCT3’ For β-actin forward
primer-5’ CCTGGCACCCAGCACAAT 3’, reverse pri-
mer- 5’ GCCGATCCACACGGAGTACT3’. PCR program:
95 °C for 10 min, 40 cycles of {95 °C for 15 s and 62 °C for
1 min}. The experiments were carried out in triplicates for
each data point. The relative gene expression was calcu-
lated for the gene of interest using the ΔΔCT method, in
which cycle threshold (CT) values were normalized to the
beta actin reference gene.
Immunofluorescent studies: For immunofluorescent
staining of p53, cells were grown on coverslips, fixed
with 4 % paraformaldehyde, permeabilized with 0.5 %
Triton X-100 and stained overnight with the PAb1620
(WT conformation) (Calbiochem) or PAb240 (mutant
conformation) (Calbiochem) antibodies and then with
FITC-labeled (green) secondary antibody, goat anti-
mouse IgG (millipore). DAPI fluoromount (blue)
(Southern Biotech) was used for nuclei labeling. The
cells were examined by fluorescence microscopy.
Quantitative measurements of the fluorescent signal:
Staining intensity of a fluorescent PAb240 and PAb1620
antibody were recorded using an indirect method. The
digitized images were processed to determine quantita-
tive measure for the specific fluorescence signal (the
background and nuclear blue corrected fluorescence in
the object) using existing tools in the widely used image
processing software Photoshop from Adobe. The region
of interest was defined in the TIFF format image, where
the 3 RGB channels, blue, red and green are encoded as
separate layers. Using the histogram function in Photoshop
we determined the intensity of the light (fluorescence) for
that individual color channel.
Cell treatment: U251 and U87 cell lines were plated in
triplicates for 24 h in order to allow adherence. ZnCl2
(Sigma-Aldrich) was added at final concentration of
100 μM.
Results
We analyzed whole genome expression data of a discovery
set of 67 untreated tumors from GBM patients to find
novel survival biomarkers. Patients were grouped to short
(S) (less than 300 days), long (L) (more than 1095 days-
3 years) and intermediate (I) (between 300 to 1095 days)
survival. First, to get the most effective survival markers
intermediate survival samples were eliminated. dChip
class neighbors analysis revealed that a group of metallo-
thionein genes clustered the 8 short survival and 7 long
survival samples. Expression of Metallothionein-3, 1 F,
1H, 1A, 1E and 1B were relatively much higher in short
survival patients compared to long survival patients
(Fig. 1a). Mean RNA expression comparison of these MTs
in all the samples and in normal brain tissue revealed that
Fig. 1 a Illustration of different MTs expression in 15 untreated patients with short (S) Intermidiate (I) and long (L) survival – a ‘heat map’. Largest
relative gene expression values are displayed in red, the smallest relative values in green and intermediate values in shades of black. b Mean
expression values of different MTs in 67 untreated patients with short (S) long (L) and intermediate (I) survival and 7 (N) normal brain
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MT expression in long survival patients is similar to
normal brain whereas in intermediate and short sur-
vival the expression is higher (Fig. 1b). MT3 and MT1f
showed the most significant difference between long
and short survival patients (p-value 0.003 for both),
thereafter, MT1B and MT1A, both with p-value 0.011
and finally MT1G p-value 0.012. Since there is a high
positive correlation between MT3 and MT1F expres-
sion (r = 0.87 p = 0.004E−13) we continued our study
with MT3.
As indicated, high MT expression may lead to an
inactive p53 which is crucial in alkylating agent induced
apoptosis. We looked for a cellular model for patients
that have WT p53 but due to high levels of MTs, the
misfolded conformation turns WTp53 to an inactive
form. Quantification of MT3 expression in normal astro-
cytes, U251 and U87 glioma cell lines revealed that MT3
is elevated more than 4 fold in U87 cells (Fig. 2), com-
pared to normal astrocytes.
We checked the p53 conformation in the U251 and
U87cell lines by immunofluorecent labeling with the
conformation-specific antibodies PAb1620 (for p53 wild-
type, folded conformation) and PAb240 (for p53 mutant
unfolded conformation). U251 harbors R273H mutation
(The Tp53 mutation web site http://p53.free.fr/Database/
Cancer_cell_lines/p53_cell_lines.html) and indeed these
cells showed p53 inactive conformation (Fig. 3a). U87
on the other hand is known to harbor wild type p53
(The Tp53 mutation web site http://p53.free.fr/Database/
Cancer_cell_lines/p53_cell_lines.html). Surprisingly, how-
ever, immunofluorescent staining with the specific WT
(PAb1620) and mutant (PAb240) antibodies, respectively,
revealed that most of the U87 p53 is in a mutant conform-
ation. Thus, although p53 is not mutated in this cell line
its conformation is inactive. As zinc can restore p53
function by changing the conformation from a non active
to an active conformation [23], we tested whether addition
of zinc can rescue p53 conformation in U87 cells. Indeed,
zinc supplementation decreased mutant conformation
and increased p53 wild type conformation phenotype in
U87 (Fig. 3b). Quantitative measurements of the fluores-
cent signal intensity of a fluorescent PAb240 and PAb1620
antibody confirmed the increased p53 wild type conform-
ation phenotype upon addition of zinc (Zn) (Fig. 4).
Next we checked the expression of MTs in 210 samples
from The Cancer Genome Atlas (TCGA). We used TCGA
portal, cBio Cancer Genomics Portal (http://cbioportal.org/).
Table 1 enlists Affymetrix probes used for MTs and HIPK2
analysis. There were 71 samples with short survival, 113
with intermediate survival and 22 with long survival. Four
samples were excluded because of missing data of either
survival time orMT expression. All MTs that were quanti-
fied in this study had significantly higher mean expression
intensity in short survival patients compared to long sur-
vival patients (Fig. 5a) (3.6 times for MT1E, 2.5 for MT1F,
4.2 times for MT1H, 3.2 times for MT1M, 1.8 times for
MT1x, 3.9 times for MT2A and 1.5 times for MT3).
MT1G expression intensity was much higher than all
others, yet its expression is 1.8 times higher in short
survival patients compared to long survival patients.
Kaplan–Meier survival curve overlapping TCGA study
core samples also illustrated shorter survival correlated to
high MT expression. For MT2A (Fig. 5b) among the 210
samples there were 5 up-regulated samples, 14 down-
regulated samples and 190 intermediary samples. The sig-
nificance of difference in survival between groups of sam-
ples was calculated by log-rank p-value. Log-rank p-
value of up-regulated vs. down-regulated is 0.054.
Log-rank p-value of up-regulated vs. intermediary is















Fig. 2 MT3 expression in U251 and U87 GBM cell lines relative to normal astrocytes. Relative quantification (RQ) is reported as means ± SD of
triplicates and statistical significance was determined by one-way ANOVA and post hoc Tukey’s test. *- P < 0.05 compared to NHA and to U251
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intermediary is 0.0139. Similar results were inspected for
MT1f: 21 up-regulated samples; 22 down-regulated
samples and 167 intermediary samples. Log-rank p-value
of up-regulated vs. down-regulated is 0.0132. Log-
rank p-value of up-regulated vs. intermediary is 0.23
and log-rank p-value of down-regulated vs. intermediary
is 0.0145. For MT1a the results were not significant: 40
up-regulated samples, 50 down-regulated samples and
121 intermediary samples. Log-rank p-value of up-
regulated vs. down-regulated is 0.196. Log-rank p-value of
up-regulated versus intermediary is 0.27 and log-rank
p-value of down-regulated versus intermediary is 0.07.
For MT3 there were 46 up-regulated samples, 33
down-regulated samples and 125 intermediary sam-
ples. Log-rank p-value of up-regulated versus down-
regulated is 0.09. Log-rank p-value of up-regulated
versus intermediary is 0.27 and log-rank p-value of
down-regulated vs intermediary is 0.056. Next, we an-
alyzed the TCGA expression data to test whether
HIPK2 expression in GBM also correlate with GBM
survival. HIPK2 expression can be estimated by two
Affymetrix probes (213763_at and 219028_at) on the
chip. As expected, HIPK2 mean expression intensity is
lower in short survival patients compared to long
Fig. 3 a p53 conformation is inactive in U251 cell line. Fluorescent microscope image with 4× objective of U251 cells stained with DAPI for nuclei (blue)
and FITC (green) Ab for wild type (WT) p53 (PAb1620) or FITC Ab for Mutant (MT) p53 (PAb240). b p53 conformation in U87 cell line changes to active
form upon zinc addition. Untreated /zinc treated superimposed fluorescent microscope image with 10× objective of U87 stained with DAPI for nuclei
(blue) and FITC (green) Ab for wild type (WT) p53 (PAb1620) or FITC Ab for Mutant (MT) p53 (PAb240). After zinc supplementation in U87 cells, p53
conformation changed from inactive mutant like to active WT like
Fig. 4 P53 conformation quantification in U87 before (control) and after addition of zinc (Zn). P53 conformation detected by FITC labeled (green)
secondary antibody to PAb240 (mutant like conformation) and PAb1620 (wild type conformation), intensity (pixels) per cell is plotted for each
conformation with and without zinc addition
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survival patients by 1.5 for 213763_at and 1.4 for
213763_at HIPK2 Affymetrix probes (Fig. 5c). Student
T-test p value: 0.009 and 0.0002, respectively. Kaplan–
Meier survival curve overlapping TCGA study core for
210 samples also illustrates shorter survival correlated
to low HIPK2 expression (Fig. 5d). In these samples
there were 23 up-regulated, 25 down-regulated and 165
patients with intermediary HIPK2 expression. The sig-
nificance of difference between survival groups of sam-
ples was calculated. The log-rank p-value is as follow:
up-regulated versus down-regulated is 0.0015, up-
regulated versus intermediary is 0.2653, down-regulated
vs. intermediary is 0.0025. We determined the value of
correlation coefficient between MT probes and HIPK2
probe. For visual display of the correlation coefficients
betweenMTs and HIPK2 pairs of probes, we formed ‘heat-
map’ illustrated in Fig. 6. In this diagram the color in each
cell represents the value of the correlation coefficient be-
tween the values shown by a particular pair of probes. Red
color represents highly positive correlation of expression
and blue represents negative correlation. The values on
the main diagonal are all 1, since the correlation coeffi-
cient for a value matched with itself is 1. The value of the
correlation coefficient between allMTs is strongly positive.
On the other hand all 12MT probe expression were found
to be negatively correlated to HIPK2 probe expression in
these patients (R = -0.2, p = 0.002).
Since low HIPK2 and high MTs expression were found
to be associated with lower survival in GBM patients, we
checked the number of samples with low HIPK2 and
high MT expression in TCGA cohort. 71 out of 210
(34 %) samples had this pattern of expression. In these
GBM samples, MT associated zinc depletion may
enforce inactive p53 conformation and thus may lead to
decreased response to chemotherapy. Interestingly, in
addition to the expected high expressed MTs in low
HIPK2 expressed GBM samples (71), there were also 35
(16 %) GBM samples that expressed high amounts of
MTs and high amounts of HIPK2. Thus in GBM, MTs
may be highly expressed irrespective to HIPK2 level.
These patients may also exhibit zinc depletion.
Discussion
Our understanding of GBM tumors has expanded sig-
nificantly recently. Outcomes and patient prognosis rely
on histological classification combined with information
on patient age and tumor size and location. However,
high heterogeneity of GBM tumors among patients
makes the prognosis prediction very difficult. Therefore,
more individualized biomarkers may lead to better
Fig. 5 a MTs mean expression in short, intermediate (Int) and long survival GBM patients. M1E, Mt1F, MT1H, MT1M, MT1X, MT2A and MT3 mean
expression intensity is higher in short survival patients compared to long survival patients. b Kaplan–Meier survival curve for MT2A expression. Red line- up
regulated MT2A; green line- down regulated MT2A; black line - intermediate expression. c HIPK2 mean expression intensity and survival in GBM samples.
HIPK2 Affymetrix probes (213763_at in red and 219028_at in blue). HIPK2 is higher in high survival patients compared to low survival patients in both
probe sets. d Kaplan–Meier survival curve for HIPK2 expression. Red line- up regulated HIPK2; green line- down regulated HIPK2; black
line- intermediate expression
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prognosis prediction and the development of novel spe-
cific targeted therapy. In search for such biomarker we
analyzed 67 GBM clinical tumor samples and revealed
that high MTs levels are associated with poor survival
whereas low levels are associated to relatively good sur-
vival. We validated the results of the discovery cohort by
analysis of expression data of 210 GBM patients from
the TCGA database. We show here that a subset of
GBM patients with high levels of MTs have decreased
survival. Likewise, poor survival is observed in GBM
patients with low levels of HIPK2. These observations
were not always concurrent in the same patients. In fact,
there are GBM patients with high MTs and high HIPK2.
Thus, in addition to the established correlation between
MT expression and HIPK2 we suggest that other regula-
tion mechanisms, such as epigenetic methylation [29]
may increase MT expression even when HIPK2 level is
normal. Hence, HIPK2 and MT levels (as a whole or even
one or two sub isoforms such as MT3/MT2A) may serve
as survival predictors independently. MTs may affect
GBM in many ways: 1) High levels of MTs may bind alkyl-
ating agents and confer resistance to chemotherapy 2)
MTs bind zinc and switch p53 folding to the inactive form
and thus prevent chemotherapy-activated p53 mediated
apoptosis. 3) MT in its apo-form may interact with p53
and prevent inflection of gene transcription and apoptosis
by P53. 4) MTs may add to the infiltrative feature of
gliomas by enhancing migration, as has been shown with
MT1E [19]. In addition, U87 GBM cell line may serve as a
model for inactive p53 conformation without mutation. In
these cells we were able to rescue p53 conformation to an
active form by zinc. Thus, GBM patients exert several
modes of p53 inactivation which has survival indication
and can be targeted by precise treatment. MTs expression
may serve as a novel individualized prognostic indicator
for prediction of GBM overall survival and also serve as
treatment target. Another novel finding of our study is
that subsets of patients with WT p53 express high levels
of MTs resulting in low levels of zinc and inactive p53
even if there is no mutation in p53. The high MTs in these
patients may deplete intracellular Zn levels and also
Fig. 6 Heat map correlation coefficients between 12 probes of MTs. MT1X, MT1G, MT3, MT1H, MT1X, MT1P2, MT2A, MT1E, MT1F, MT1M, MT1F, MT1M (#1-12)
expression and two probes (#13, 14) of HIPK2 expression (Table 1). Red color represents highly positive correlation of expression and blue
represents negative correlation. All MTs are highly positive (red) correlated to each other and negatively correlated (blue) to HIPK2 probe
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interact with alkylating agents (chemotherapy) thus lower-
ing response to treatment. In this setting the prognosis is
poor and these GBM patients are expected to have short
survival.
Conclusions
Our study demonstrates that high metallothionein levels
in GBM patients are associated with poor survival. There-
fore, MT expression may be a potential novel prognostic
biomarker for GBM. In addition, we have discovered that
the p53 conformation in GBM U87 cell line is inactive
and can be altered to the active form by addition of zinc.
Thus GBM U87 cell line may be a good model for patients
with non active WT p53 resulting from high levels of MTs
without mutations in the p53 gene.
Availability of supporting data
The TCGA GBM samples Affymetrix Affy HT Human
Genome U133 expression data are publicly available at:
TCGA data portal (https://tcga-data.nci.nih.gov/tcga).
Abbreviations
GBM: Glioblastoma multiforme; MT: Metallothionein; NHA: Normal human
astrocytes; RT-PCR: Real-time polymerase chain reaction; RQ: Relative
quantification; WHO: World health organization; ZnCL2: Zinc chloride.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RMS conceived of the project, carried out molecular genetic studies, participated
in the collection and analysis of all data sources including statistical analysis and
drafted the manuscript, MY participated in the design and coordination,
AJS participated in the design of the study and helped to draft the manuscript,
EE participated in the collection, analysis of all data sources and performed the
statistical analysis, TP carried out the viability and immunofluorescent assays,
IM carried out the viability assays, SC participated in the design of the study,
AT conceived of the study, and participated in its design and coordination.




We would like to thank Dr. Chaya Brodie, Bar-Ilan Institute, Israel for the kind
gift of normal astrocytes.
Funding
This study was supported by the departmental Sheba Medical Center funds.
Author details
1Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and
Cancer Research Center, Sheba Medical Center, Tel Hashomer affiliated to
the Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
2Department of Pediatric Neurosurgery, Dana Children’s Hospital,
Tel-Aviv-Sourasky Medical Center, Tel-Aviv, Israel.
Received: 24 March 2015 Accepted: 21 September 2015
References
1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al.
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes
Dev. 2007;21(21):2683–710.
2. Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H, et al. Coexistence of EGFR with KRAS, or
BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation
profiling from 5125 Chinese cohorts. Br J Cancer. 2014 May 27;110(11):2812–20.
doi: 10.1038/bjc.2014.210. Epub 2014 Apr 17.
3. Chaudhry NS, Shah AH, Ferraro N, Snelling BM, Bregy A, Madhavan K, et al.
Predictors of long-term survival in patients with glioblastoma multiforme:
advancements from the last quarter century. Cancer Investig. 2013;31(5):287–308.
4. Brower JV, Clark PA, Lyon W, Kuo JS. MicroRNAs in cancer: Glioblastoma and
glioblastoma cancer stem cells. Neurochem Int. 2014.
5. Chiang JH, Cheng WS, Hood L, Tian Q. An epigenetic biomarker panel for
glioblastoma multiforme personalized medicine through DNA methylation
analysis of human embryonic stem cell-like signature. Omics J Integ Biol.
2014;18(5):310–23.
6. Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making
for malignant gliomas. Curr Treat Options in Oncol. 2012;13(4):417–36.
7. Jain R, Poisson LM, Gutman D, Scarpace L, Hwang SN, Holder CA, et al.
Outcome prediction in patients with glioblastoma by using imaging,
clinical, and genomic biomarkers: focus on the nonenhancing component
of the tumor. Radiology. 2014;272(21):4841–93. 1316911.
8. Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation,
degradation, and biological significance of mammalian metallothioneins.
Crit Rev Biochem Mol Biol. 2000;35(1):35–70.
9. Stennard FA, Holloway AF, Hamilton J, West AK. Characterisation of six additional
human metallothionein genes. Biochim Biophys Acta. 1994;1218(3):357–65.
10. Palmiter RD, Findley SD, Whitmore TE, Durnam DM. MT-III, a brain-specific
member of the metallothionein gene family. Proc Natl Acad Sci U S A.
1992;89(14):6333–7.
11. Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP, et al.
Induction of a new metallothionein isoform (MT-IV) occurs during differentiation
of stratified squamous epithelia. Biochemistry. 1994;33(23):7250–9.
12. Dunn MA, Blalock TL, Cousins RJ. Metallothionein. Proc Soc Exp Biol Med.
1987;185(2):107–19.
13. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D, et al. Restoring
wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein
and zinc. Exp Cell Res. 2009;315(1):67–75.
14. Habel N, Hamidouche Z, Girault I, Patino-Garcia A, Lecanda F, Marie PJ, et al.
Zinc chelation: a metallothionein 2A’s mechanism of action involved in
osteosarcoma cell death and chemotherapy resistance. Cell Death Dis.
2013;4:e874.
15. Falnoga I, Zelenik Pevec A, Slejkovec Z, Znidaric MT, Zajc I, Mlakar SJ,
et al. Arsenic trioxide (ATO) influences the gene expression of
metallothioneins in human glioblastoma cells. Biol Trace Elem Res.
2012;149(3):331–9.
16. Petering DH, Zhu J, Krezoski S, Meeusen J, Kiekenbush C, Krull S, et al.
Apo-metallothionein emerging as a major player in the cellular activities
of metallothionein. Exp Biol Med (Maywood). 2006;231(9):1528–34.
17. Ostrakhovitch EA, Olsson PE, Jiang S, Cherian MG. Interaction of metallothionein
with tumor suppressor p53 protein. FEBS Lett. 2006;580(5):1235–8.
18. Xia N, Liu L, Yi X, Wang J. Studies of interaction of tumor suppressor p53
with apo-MT using surface plasmon resonance. Anal Bioanal Chem.
2009;395(8):2569–75.
19. Ryu HH, Jung S, Jung TY, Moon KS, Kim IY, Jeong YI, et al. Role of metallothionein
1E in the migration and invasion of human glioma cell lines. Int J Oncol.
2012;41(4):1305–13.
20. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, et al. Reversible
dysfunction of wild-type p53 following homeodomain-interacting protein
kinase-2 knockdown. Cancer Res. 2008;68(10):3707–14.
21. Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, et al. Zinc
supplementation augments in vivo antitumor effect of chemotherapy by
restoring p53 function. Int J Cancer J Int Cancer. 2012;131(4):E562–8.
22. Puca R, Nardinocchi L, Givol D, D’Orazi G. Regulation of p53 activity by HIPK2:
molecular mechanisms and therapeutical implications in human cancer cells.
Oncogene. 2010;29(31):4378–87.
23. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, et al. Restoring
p53 active conformation by zinc increases the response of mutant p53 tumor
cells to anticancer drugs. Cell Cycle. 2011;10(10):1679–89.
24. Comprehensive genomic characterization defines human glioblastoma
genes and core pathways.Cancer Genome Atlas Research Network. Nature.
2008;455(7216):1061–1068.
25. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative
tumour-derived p53 mutants reveals that changes in protein conformation are
Mehrian-Shai et al. BMC Medical Genomics  (2015) 8:68 Page 8 of 9
not correlated with loss of transactivation or inhibition of cell proliferation.
EMBO J. 1994;13(15):3496–504.
26. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of
mutant p53 conformation and function. Science. 1999;286(5449):2507–10.
27. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common
p53 cancer mutants. Oncogene. 2007;26(15):2226–42.
28. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation.
Cancer Cell. 2012;21(5):614–25.
29. Majumder S, Kutay H, Datta J, Summers D, Jacob ST, Ghoshal K. Epigenetic
regulation of metallothionein-i gene expression: differential regulation of
methylated and unmethylated promoters by DNA methyltransferases and
methyl CpG binding proteins. J Cell Biochem. 2006;97(6):1300–16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mehrian-Shai et al. BMC Medical Genomics  (2015) 8:68 Page 9 of 9
